サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1574948

カテーテル関連血流感染（CRBSI）治療市場：薬剤クラス別、投与経路別、適応症別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年の予測

CRBSI Treatment Market, By Drug Class, By Route of Administration, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 303 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
カテーテル関連血流感染（CRBSI）治療市場：薬剤クラス別、投与経路別、適応症別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年10月02日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

カテーテル関連血流感染（CRBSI）治療市場規模は2023年に15億3,032万米ドルとなり、2024年から2032年にかけてCAGR 5.20％で拡大

カテーテル関連血流感染（CRBSI）治療市場- 市場力学

カテーテル関連血流感染の蔓延が効果的な治療への需要を押し上げる

カテーテル関連血流感染（CRBSI）治療の流行増加は、CRBSI治療市場の重要な促進要因です。CRBSIに関連するリスクに対する患者やヘルスケア提供者の意識の高まりが、予防戦略の重視につながっています。ヘルスケア部門が患者の安全を優先し、院内感染の削減に努める中、CRBSI治療に対する需要は拡大し続けており、ヘルスケア市場における研究開発の重要な分野となっています。

米国疾病予防管理センター（CDC）によると、米国では毎年約25万件の血流感染症が発生しており、その多くが中心静脈カテーテルに関連しています。このことは、効果的な治療と予防措置の緊急の必要性を浮き彫りにしています。ヘルスケア機関では、抗菌薬含浸カテーテルなどの高度な感染制御プロトコルの採用や、カテーテルケアに関する医療スタッフへのトレーニング強化が進んでいます。

CRBSI治療市場-主要インサイト

当社のリサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約5.20%のCAGRで毎年成長すると予測されています。

薬剤クラス別では、バンコマイシンが2023年に最大の市場シェアを示すと予測されます。

適応症別では、細菌感染症が2023年の主要タイプでした。

投与経路別では、2023年には注射剤が主要タイプとなっています。

地域別では、北米が2023年の売上高でトップ

CRBSI治療市場-セグメンテーション分析：

世界のCRBSI治療市場は薬剤クラス別、投与経路別、適応症別、地域別に区分されます。

市場は薬剤クラス別に7つに分類される：クロキサシリン、セフタジジム、セファゾリン、ダプトマイシン、バンコマイシン、テイコプラニン、エキノカンジン、その他。バンコマイシンはCRBSI治療市場において最も支配的なセグメントです。この抗生物質は、CRBSIの原因となるメチシリン耐性黄色ブドウ球菌（MRSA）によく効く。信頼性が高く、多くの種類の細菌に有効であるため、ヘルスケアプロバイダーに好まれています。バンコマイシンは長い間使用されており、安全性の実績も高いため、より信頼されています。抗生物質耐性が増加する中、バンコマイシンのような効果的な治療の必要性は依然として高いです。全体として、その有効性と医療従事者からの信頼は、CRBSI治療のトップに君臨し続けています。

市場は適応症別に、3つのカテゴリーに分けられる：細菌感染症、真菌感染症、ウイルス・寄生虫感染症、その他です。細菌感染症はカテーテル関連血流感染（CRBSI）治療市場の最大の部分を占めています。細菌はこれらの感染症の最も一般的な原因であり、深刻な健康問題につながる可能性があります。治療には通常、多くの種類の細菌に有効な抗生物質が用いられます。カテーテルを使用している患者における細菌感染症が多いことから、これらの治療に対する需要が高まっています。また、ヘルスケアプロバイダーは細菌感染による合併症を減らすために迅速な解決策に重点を置いており、この部分が市場のさらなる成長を後押ししています。

CRBSI治療市場-地理的洞察

北米のカテーテル関連血流感染（CRBSI）治療市場は急速に成長しています。この成長は主に、より多くの人々が病院に入院し、中心静脈カテーテルを使用しているためです。病院はより良い感染対策に注力しており、効果的な治療に対する需要が高まっています。感染制御プログラムに対する政府の支援もこの市場の重要な促進要因です。ヘルスケア規制の強化により、病院は改善された手法や製品を採用するようになっています。その結果、患者はより安全で効果的な治療を受けられるようになっています。

CRBSI治療市場-競合情勢：

カテーテル関連血流感染（CRBSI）治療市場は競合が激しく、バードメディカル（BD）、メドトロニック、テレフレックスなどの重要企業が参入しています。バードメディカルは革新的なカテーテルデザインで知られています。メドトロニックは世界中で幅広い製品を提供しています。テレフレックスは感染予防のための先進的なデザインで患者の安全性を重視しています。

スミスメディカルはバスキュラーアクセスに特化し、品質と安全性を重視しています。フレゼニウス・カビはクリティカルケア製品で有名であり、アンギオダイナミクスは低侵襲処置に重点を置いています。B. Braun Melsungen AGは、様々な医療機器を提供し、持続可能性を重視しています。これらの企業は、新しいソリューションの創造と感染予防の改善に努め、市場を活発でダイナミックなものにしています。

目次

第1章 カテーテル関連血流感染（CRBSI）治療市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 CRBSIの主要市場動向

  • 治療市場促進要因
  • 治療市場抑制要因
  • 治療市場の機会
  • 治療市場の将来動向

第4章 CRBSI業界調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 カテーテル関連血流感染（CRBSI）治療市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 カテーテル関連血流感染（CRBSI）治療市場情勢

  • CRBSI治療市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 カテーテル関連血流感染（CRBSI）治療市場-薬剤クラス別

  • 概要
    • 薬剤クラス別セグメントシェア分析
    • クロキサシリン
    • セフタジジム
    • セファゾリン
    • ダプトマイシン
    • バンコマイシン
    • テイコプラニン
    • エキノキャンディン
    • その他

第8章 カテーテル関連血流感染（CRBSI）治療市場- 投与経路別

  • 概要
    • 投与経路別セグメントシェア分析
    • 経口
    • 注射可能

第9章 カテーテル関連血流感染（CRBSI）治療市場- 適応症別

  • 概要
    • 適応症別セグメントシェア分析
    • 細菌感染症
    • 真菌感染症
    • ウイルスおよび寄生虫感染症
    • その他

第10章 カテーテル関連血流感染（CRBSI）治療市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋地域
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析-CRBSI治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Bard Medical
    • Medtronic
    • Teleflex
    • Smith's Medical
    • Halyard Health
    • Fresenius Kabi
    • AngioDynamics
    • Vygon
    • B. Braun Melsungen AG
    • Nipro Corporation
    • Cook Medical
    • Amsino International
    • Merit Medical Systems
    • Pall Corporation
    • CR Bard
    • Ruhof Healthcare
    • Inspire Medical Systems
    • Abbott Laboratories

第12章 アナリストの全方位展望

目次
Product Code: ANV3951

REPORT HIGHLIGHT

CRBSI Treatment Market size was valued at USD 1,530.32 Million in 2023, expanding at a CAGR of 5.20% from 2024 to 2032.

CRBSI stands for Catheter-Related Bloodstream Infections. It happens when bacteria enter the bloodstream through a catheter, a tube used for medical treatments. The treatment market for CRBSI includes various products and therapies designed to prevent and manage these infections. This market offers antibiotics, antiseptics, and advanced catheter designs that reduce infection risk. Hospitals and healthcare providers invest in these solutions to improve patient safety and outcomes. The goal is to minimize infections, which can lead to serious health issues and longer hospital stays.

CRBSI Treatment Market- Market Dynamics

The prevalence of catheter-related infections boosts demand for effective treatments.

The rising prevalence of catheter-related bloodstream infections (CRBSI) is a significant driver for the CRBSI treatment market. Growing awareness among patients and healthcare providers about the risks associated with CRBSIs is leading to a greater emphasis on prevention strategies. As the healthcare sector prioritizes patient safety and strives to reduce hospital-acquired infections, the demand for CRBSI treatments continues to grow, making it a crucial area for research and development in the healthcare market.

According to the Centers for Disease Control and Prevention (CDC), about 250,000 cases of bloodstream infections occur in the U.S. each year, with many linked to central line catheters. This highlights the urgent need for effective treatments and preventive measures. Healthcare institutions are increasingly adopting advanced infection control protocols, such as antimicrobial-impregnated catheters, and enhanced training for healthcare staff on catheter care.

CRBSI Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.20% over the forecast period (2024-2032)

Based on Drug Class segmentation, Vancomycin was predicted to show maximum market share in the year 2023

Based on indication, Bacterial Infections was the leading type in 2023

Based on Route of Administration segmentation, Injectable was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

CRBSI Treatment Market- Segmentation Analysis:

The Global CRBSI Treatment Market is segmented based on Drug Class, Route of Administration, Indication, and Region.

The market is divided into Seven categories based on Drug Class: Cloxacillin, Ceftazidime, Cefazoline, Daptomycin, Vancomycin, Teicoplanin, Echinocandin, and Others. Vancomycin is the most dominant segment in the CRBSI treatment market. This antibiotic works well against methicillin-resistant Staphylococcus aureus (MRSA), which often causes these infections. Healthcare providers like it because it is reliable and effective against many types of bacteria. Vancomycin has been used for a long time and has a strong safety record, making it even more trusted. As antibiotic resistance increases, the need for effective treatments like Vancomycin is still high. Overall, its effectiveness and the trust of medical professionals keep it at the top of CRBSI treatment.

The market is divided into three categories based on the Indication: Bacterial Infections, Fungal Infections, Viral and Parasitic Infections, and Others. Bacterial infections are the biggest part of the CRBSI (Catheter-Related Bloodstream Infection) treatment market. bacteria are the most common cause of these infections and can lead to serious health problems. Treatments usually involve antibiotics, which are effective against many types of bacteria. The high number of bacterial infections in patients with catheters increases the demand for these treatments. Also, healthcare providers focus on quick solutions to reduce complications from bacterial infections, which helps this part of the market grow even more.

CRBSI Treatment Market- Geographical Insights

North America's catheter-related bloodstream infection (CRBSI) treatment market is growing quickly. This growth is mainly because more people are admitted to hospitals and using central venous catheters. Hospitals are focusing on better infection control, increasing the demand for effective treatments. Government support for infection control programs is also an important driver for this market. Stricter healthcare regulations encourage hospitals to adopt improved practices and products. As a result, patients are receiving safer and more effective care.

CRBSI Treatment Market- Competitive Landscape:

The catheter-related bloodstream infections (CRBSI) market is competitive and includes important companies like Bard Medical (BD), Medtronic, and Teleflex. Bard Medical is known for its innovative catheter designs. Medtronic offers a wide range of products around the world. Teleflex focuses on patient safety with advanced designs to prevent infections.

Smith's Medical specializes in vascular access and puts a strong emphasis on quality and safety. Fresenius Kabi is well-known for its critical care products, and AngioDynamics focuses on minimally invasive procedures. B. Braun Melsungen AG offers a variety of medical devices and values sustainability. These companies work hard to create new solutions and improve infection prevention, making the market active and dynamic.

Recent Developments:

In August 2023, Citius Pharmaceuticals, Inc. announced a significant milestone for the clinical trial of Mino-Lok, an antibiotic lock solution designed to preserve catheters in patients with catheter-related bloodstream infections. The company reported that all 92 required events to complete the trial have been achieved. Some patients are still undergoing treatment, which may result in additional events.

In July 2023, Teva Pharmaceuticals, Inc. and Alvotech revealed their intention to strengthen their existing strategic partnership aimed at developing and launching several biosimilar candidates. As part of this collaboration, Teva will invest an additional US$ 40 million by purchasing subordinated convertible bonds to be issued by Alvotech.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CRBSI TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Bard Medical
  • Medtronic
  • Teleflex
  • Smith's Medical
  • Halyard Health
  • Fresenius Kabi
  • AngioDynamics
  • Vygon
  • B. Braun Melsungen AG
  • Nipro Corporation
  • Cook Medical
  • Amsino International
  • Merit Medical Systems
  • Pall Corporation
  • C.R. Bard
  • Ruhof Healthcare
  • Inspire Medical Systems
  • Abbott Laboratories

GLOBAL CRBSI TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Cloxacillin
  • Ceftazidime
  • Cefazoline
  • Daptomycin
  • Vancomycin
  • Teicoplanin
  • Echinocandin
  • Others

GLOBAL CRBSI TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable

GLOBAL CRBSI TREATMENT MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Bacterial Infections
  • Fungal Infection
  • Viral and Parasitic Infections
  • Others

GLOBAL CRBSI TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. CRBSI Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. CRBSI Treatment Market Snippet by Drug Class
    • 2.1.2. CRBSI Treatment Market Snippet by Route of Administration
    • 2.1.3. CRBSI Treatment Market Snippet by Indication
    • 2.1.4. CRBSI Treatment Market Snippet by Country
    • 2.1.5. CRBSI Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. CRBSI Key Market Trends

  • 3.1. CRBSI Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. CRBSI Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. CRBSI Treatment Market Opportunities
  • 3.4. CRBSI Treatment Market Future Trends

4. CRBSI Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. CRBSI Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. CRBSI Treatment Market Landscape

  • 6.1. CRBSI Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. CRBSI Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Cloxacillin
    • 7.1.3. Ceftazidime
    • 7.1.4. Cefazoline
    • 7.1.5. Daptomycin
    • 7.1.6. Vancomycin
    • 7.1.7. Teicoplanin
    • 7.1.8. Echinocandin
    • 7.1.9. Others

8. CRBSI Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectable

9. CRBSI Treatment Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 9.1.2. Bacterial Infections
    • 9.1.3. Fungal Infection
    • 9.1.4. Viral and Parasitic Infections
    • 9.1.5. Others

10. CRBSI Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. CRBSI Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. CRBSI Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. CRBSI Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. CRBSI Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. CRBSI Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- CRBSI Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Bard Medical
    • 11.2.2. Medtronic
    • 11.2.3. Teleflex
    • 11.2.4. Smith's Medical
    • 11.2.5. Halyard Health
    • 11.2.6. Fresenius Kabi
    • 11.2.7. AngioDynamics
    • 11.2.8. Vygon
    • 11.2.9. B. Braun Melsungen AG
    • 11.2.10. Nipro Corporation
    • 11.2.11. Cook Medical
    • 11.2.12. Amsino International
    • 11.2.13. Merit Medical Systems
    • 11.2.14. Pall Corporation
    • 11.2.15. C.R. Bard
    • 11.2.16. Ruhof Healthcare
    • 11.2.17. Inspire Medical Systems
    • 11.2.18. Abbott Laboratories

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us